ArticleJournal of neuro-oncology2016
Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide.
Article in Journal of neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Acute Neurological Complications of Brain Tumors and Immune Therapies, a Guideline for the Neuro-hospitalist.Current neurology and neuroscience reports · 2020Guideline
- Epilepsy in Patients with Gliomas.Neurologia medico-chirurgica · 2024Review
- Disease Assessments in Patients with Glioblastoma.Current oncology reports · 2023Review
- Clinical Management of Diffuse Low-Grade Gliomas.Cancers · 2020Review
- Article
- Perampanel Add-on to Standard RadiochemotherapyFrontiers in neuroscience · 2020Article
- Scale-Free Analysis of Intraoperative ECoG During Awake Craniotomy for Glioma.Frontiers in oncology · 2020Article
- Seizure response to temozolomide chemotherapy in patients with WHO grade II oligodendroglioma: a single-institution descriptive study.Neuro-oncology practice · 2019Article
- Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review.Oncotarget · 2018Article
- Lacosamide in patients with gliomas and uncontrolled seizures: results from an observational study.Journal of neuro-oncology · 2018Observational
- Seizure response to perampanel in drug-resistant epilepsy with gliomas: early observations.Journal of neuro-oncology · 2017Article
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials.Neuro-oncology · 2017Review
- Peritumoural glutamate correlates with post-operative seizures in supratentorial gliomas.Journal of neuro-oncology · 2016Article
- Long-range and short-range tumor-stroma networks synergistically contribute to tumor-associated epilepsy.Oncotarget · 2016Review
- Seizures and gliomas--towards a single therapeutic approach.Nature reviews. Neurology · 2016Review
- Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop.Neuro-oncology advancesReview
- Comprehensive Analysis Reveals a 4-Gene Signature in Predicting Response to Temozolomide in Low-Grade Glioma Patients.Cancer control : journal of the Moffitt Cancer CenterArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to analyze the value of seizure reduction and radiological response as prognostic markers of survival in patients with low-grade glioma (LGG) treated with temozolomide (TMZ) chemotherapy. We retrospectively reviewed adult patients with a progressive LGG and uncontrolled epilepsy in two hospitals (VUmc Amsterdam; MCH The Hague), who received chemotherapy with TMZ between 2002 and 2014. End points were a ≥50 % seizure reduction and MRI response 6, 12 and 18 months (mo) after the start of TMZ, and their relation with progression-free survival (PFS) and overall survival (OS). We identified 53 patients who met the inclusion criteria. Seizure reduction was an independent prognostic factor for both PFS (HR 0.38; 95 % CI 0.19-0.73; p = 0.004) and OS (HR 0.39; 95 % CI 0.18-0.85; p = 0.018) after 6mo, adjusting for age and histopathological diagnosis, as well as after 12 and 18mo. Patients with an objective radiological response showed a better OS (median 87.5mo; 95 % CI 62.0-112.9) than patients without a response (median 34.4mo; 95 % CI 26.1-42.6; p = 0.046) after 12mo. However, after 6 and 18mo OS was similar in patients with and without a response on MRI. Seizure reduction is an early and consistent prognostic marker for survival after treatment with TMZ, that seems to precede the radiological response. Therefore, seizure reduction may serve as a surrogate marker for tumor response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.